Latest News on A

Financial News Based On Company


Advertisement
Advertisement

Agilent Announces Cash Dividend of 26.25 Cents per Share

https://www.01net.it/agilent-announces-cash-dividend-of-26-25-cents-per-share/
Agilent Technologies Inc. (NYSE: A) announced a quarterly dividend of 26.25 cents per share of common stock. This dividend will be paid on January 27, 2027, to shareholders of record as of January 5, 2027. Agilent is a global leader in analytical and clinical laboratory technologies, with fiscal year 2025 revenue of $6.95 billion.

Agilent declares quarterly dividend of 26.25 cents per share

https://www.investing.com/news/company-news/agilent-declares-quarterly-dividend-of-2625-cents-per-share-93CH-5037070
Agilent Technologies Inc. (NYSE:A) has announced a quarterly dividend of 26.25 cents per share of common stock. This dividend is scheduled for payment on January 27, 2027, to shareholders of record as of January 5, 2027. The company, an analytical and clinical laboratory technologies provider with $6.95 billion in revenue in fiscal year 2025, noted that future dividends are subject to board approval.

Agilent Announces Cash Dividend of 26.25 Cents per Share

https://www.joplinglobe.com/region/national_business/agilent-announces-cash-dividend-of-26-25-cents-per-share/article_bf4c4dca-9aff-5861-af08-96e33b026f4e.html
Agilent Technologies Inc. (NYSE: A) has announced a quarterly dividend of 26.25 cents per share of common stock. The dividend will be paid on January 27, 2027, to shareholders of record as of January 5, 2027. Agilent is a global leader in analytical and clinical laboratory technologies, with revenues of $6.95 billion in fiscal year 2025.

Agilent Announces Cash Dividend of 26.25 Cents per Share

https://www.businesswire.com/news/home/20261118097738/en/Agilent-Announces-Cash-Dividend-of-26.25-Cents-per-Share
Agilent Technologies Inc. (NYSE: A) declared a quarterly cash dividend of 26.25 cents per share of common stock. The dividend is scheduled to be paid on January 27, 2027, to shareholders of record as of January 5, 2027. Future dividend amounts and timing are subject to the approval of Agilent's board of directors.

Agilent declares quarterly dividend of 26.25 cents per share By Investing.com

https://uk.investing.com/news/stock-market-news/agilent-declares-quarterly-dividend-of-2625-cents-per-share-93CH-4991606
Agilent Technologies Inc. announced a quarterly dividend of 26.25 cents per share of common stock. The dividend is scheduled for payment on January 27, 2027, to shareholders of record as of January 5, 2027. The company, which specializes in analytical and clinical laboratory technologies, generated $6.95 billion in revenue in fiscal year 2025.
Advertisement

Keysight Technologies, Inc. (KEYS) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/KEYS/
This article provides a comprehensive overview of Keysight Technologies, Inc. (KEYS) stock, including its current price, news, and historical data. It covers key financial metrics like market capitalization, PE ratio, EPS, and dividend information, alongside performance comparisons with the S&P 500. The company's business segments, product offerings, and analyst ratings are also detailed.

Angelica Riemann Reports RSU Tax Withholding Surrender and Stock Purchases at Agilent Technologies

https://kalkinemedia.com/us/news/announcements/angelica-riemann-reports-rsu-tax-withholding-surrender-and-stock-purchases-at-agilent-technologies
Angelica Riemann, Senior Vice President at Agilent Technologies, Inc. (NASDAQ:A), filed a Form 4 detailing her beneficial ownership changes, including RSU tax withholding surrender and stock purchases. The transactions, dated September 30, 2026, and November 13, 2026, also included acquisitions through the Employee Stock Purchase Plan and dividend reinvestment. Following these transactions, Riemann directly holds 26,747.3327 shares of Agilent common stock.

Life Sciences and Laboratory Equipment Market Size, Share & Forecast 2036

https://www.factmr.com/report/life-sciences-and-laboratory-equipment-market
The Life Sciences and Laboratory Equipment Market is projected to reach USD 214.2 billion by 2036, growing at a CAGR of 6.9% from USD 109.9 billion in 2026. This growth is driven by expanding drug discovery, manufacturing investments by pharmaceutical companies, and increasing demand for analytical equipment and automated laboratory solutions. Key players are consolidating and integrating workflows to meet complex testing requirements and secure recurring revenue.

Form 8K Agilent Technologies For: 17 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-17-november-93CH-4964434
This article announces the filing of Form 8K by Agilent Technologies for November 17, 2026. The brief notice from Investing.com is purely informational, indicating a corporate event that requires disclosure. No specific details about the content of the Form 8K are provided within the article.

Form 8K Agilent Technologies For: 17 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-17-november-93CH-5710273
This article announces that Agilent Technologies has filed a Form 8K for November 17, 2026. The filing is brief and does not provide specific details about the content of the 8K report, which is a required submission for significant events that shareholders should know about.
Advertisement

Form 8K Agilent Technologies For: 17 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-17-november-93CH-4988271
This article announces that Agilent Technologies has filed a Form 8K for November 17. The Form 8K is a crucial document that public companies file with the SEC to announce major events that shareholders should know about. The article itself does not provide details about the content of the Form 8K.

Agilent Expands Digital Pathology Offering With U.S. Release of the Agilent S540MD Slide Scanner System

https://www.mpo-mag.com/breaking-news/agilent-expands-digital-pathology-offering-with-u-s-release-of-the-agilent-s540md-slide-scanner-system/
Agilent Technologies Inc. has launched the Agilent S540MD Slide Scanner System in the United States, an FDA-cleared whole slide imaging digital scanner. This system aims to improve diagnostic efficiency, manage growing sample volumes, and support the adoption of digital and AI-enabled workflows in pathology laboratories. The S540MD, engineered for speed and scalability with a capacity for up to 540 slides and continuous loading, is also available in several European markets.

ValueAct buys Agilent, exits Roblox, reduces Toast among Q3 moves

https://www.tradingview.com/news/seekingalpha:4da2b2984094b:0-valueact-buys-agilent-exits-roblox-reduces-toast-among-q3-moves/
ValueAct, a hedge fund, made several portfolio adjustments in the third quarter. The fund added new positions in Agilent Technologies, Medline, Ryan Specialty, and Motorola Solutions. Conversely, ValueAct exited its positions in Roblox and MongoDB, and also sold PayPay shares. The fund increased its stakes in Wix.com and Amazon while reducing its holdings in Toast and Rocket Cos.

Sequencing Consumables Market Forecast to 2035: Clinical NGS Adoption and Declining Costs to Drive Forward Growth

https://www.indexbox.io/blog/sequencing-consumables-market-forecast-to-2035-clinical-ngs-adoption-and-declining-costs-to-drive-forward-growth/
The global sequencing consumables market is predicted to experience sustained expansion, with a CAGR of 12.5% from 2026 to 2035, driven primarily by the accelerating adoption of next-generation sequencing (NGS) in clinical diagnostics and ongoing reductions in sequencing costs. Asia-Pacific is expected to lead regional growth, while clinical diagnostics and genetic testing will remain the largest and fastest-growing end-use sector. Key players include Illumina, Thermo Fisher Scientific, and Pacific Biosciences, among others.

Is Agilent Technologies (A) Fairly Valued Following Its New Product Launches?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/is-agilent-technologies-a-fairly-valued-following-its-new-pr
Agilent Technologies (A) has launched new products, including the SureSelect Cancer Research Pan Heme NGS panel and the 5987A GC/MS detector. While the company's shares trade at US$173.96, showing significant year-to-date and 3-year returns, analyst consensus suggests it is 4% undervalued with a fair value of $181.05. However, a discounted cash flow model presents a different view, indicating the stock might be overvalued with an intrinsic value of $130.88.
Advertisement

How Investors Are Reacting To Agilent Technologies (A) New Blood Cancer Test Panel

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-are-reacting-to-agilent-technologies-a-new-blo
Agilent Technologies recently launched the SureSelect Cancer Research Pan Heme panel, a new solution for profiling hematologic malignancies, expanding its tumor profiling portfolio. This move is expected to support higher recurring revenue through panels, consumables, and informatics, aligning with the company's existing investment narrative of leaning on recurring consumables and CrossLab contracts. The panel's success, alongside other product launches, could improve margin mix and predictability for Agilent, which projects significant revenue and earnings growth by 2029.

Keith Meister Sells $61M Of Illumina Stock As Shares Slip Below Sale Price

https://www.benzinga.com/trading-ideas/insider-trades/26/11/63249108/keith-meister-sells-61m-of-illumina-stock-as-shares-slip-below-sale-price
Keith Meister of Corvex Management sold 280,091 shares of Illumina Inc (NASDAQ:ILMN) for $61.1 million on November 9, 2026. The sale occurred at a weighted-average price of $218.12 per share, and Illumina's stock subsequently slipped to $208.85, 4.25% below the sale price. Meister significantly reduced his holdings but still beneficially owned 215,713 shares after the transaction.

Form 8K Agilent Technologies For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-13-november-93CH-4957298
This article announces that Agilent Technologies has filed a Form 8K on November 13. The brief notice from Investing.com provides no further details about the content of the filing but indicates it is a financial disclosure. The article also includes various market data and other news snippets, typical of an Investing.com page.

Form 8K Agilent Technologies For: 13 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-13-november-93CH-5703562
This article announces that Agilent Technologies has filed a Form 8K for November 13th. The filing is an important regulatory disclosure for investors and provides transparency on significant company events.

Agilent to Participate in 9th Annual Evercore Healthcare Conference

https://www.01net.it/agilent-to-participate-in-9th-annual-evercore-healthcare-conference/
Agilent Technologies Inc. (NYSE: A) announced its participation in the 9th Annual Evercore Healthcare Conference. Agilent management will hold a fireside chat on Tuesday, December 1, 2026, from 10 a.m. to 10:50 a.m. EST in Coral Gables, Florida. A live audio webcast and replay will be available on the company's Investor Relations website.
Advertisement

A live audio webcast will let listeners hear Agilent's Dec. 1 conference chat

https://www.stocktitan.net/news/A/agilent-to-participate-in-9th-annual-evercore-healthcare-pm87bgy97kif.html
Agilent Technologies Inc. (NYSE: A) announced its participation in the 9th Annual Evercore Healthcare Conference on December 1, 2026. Agilent management will hold a fireside chat, which will be accessible via a live audio webcast and replay on the company's Investor Relations website. The company is a global leader in analytical and clinical laboratory technologies, generating $6.95 billion in revenue in fiscal year 2025.

Agilent to Participate in 9th Annual Evercore Healthcare Conference

https://www.joplinglobe.com/region/national_business/agilent-to-participate-in-9th-annual-evercore-healthcare-conference/article_e2c8cdfe-34c5-5108-9b88-59e8fc92faef.html
Agilent Technologies Inc. (NYSE: A) announced its participation in the 9th Annual Evercore Healthcare Conference. Agilent management is scheduled for a fireside chat on Tuesday, Dec. 1, 2026, from 10 a.m. to 10:50 a.m. EST in Coral Gables, Florida, with a live audio webcast available on their Investor Relations website.

Form 8K Agilent Technologies For: 12 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-12-november-93CH-4952147
This article announces that Agilent Technologies has filed a Form 8K on November 12. The publication provides no additional details about the content of the filing but lists various financial market data.

Form 8K Agilent Technologies For: 12 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-12-november-93CH-4976751
This article reports on the filing of Form 8K by Agilent Technologies on November 12, 2026. The Form 8K is a crucial document that U.S. companies must file with the SEC to announce major events that shareholders should know about. The article provides the title and date of the filing, along with a generic image indicating Reuters as the source.

Bio-Rad Laboratories' (NYSE:BIO) Solid Profits Have Weak Fundamentals

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-nysebio-solid-profits-have-weak-fundame
Bio-Rad Laboratories' stock has not significantly moved despite strong earnings, primarily due to concerns about the sustainability of its profits. An unusual US$1.0 billion gain from non-recurring items substantially boosted reported profit, leading analysts to believe that statutory earnings may not accurately reflect the company's underlying profitability. Investors are advised to look beyond the reported profits and consider other factors like margins, growth forecasts, and potential risks.
Advertisement

What Does Agilent Technologies (A) Pan Heme Launch Mean For Investors?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/what-does-agilent-technologies-a-pan-heme-launch-mean-for-in
Agilent Technologies (NYSE:A) has launched the SureSelect Cancer Research Pan Heme NGS solution in collaboration with Roswell Park Comprehensive Cancer Center, expanding its genomic profiling capabilities to include hematologic malignancies. This new assay targets DNA and RNA genes in blood cancers, supporting personalized medicine research. While an important extension of Agilent's existing oncology tools, investors should consider it within the context of the company's broader strengths and existing market position.

Is Bruker (BRKR) A Bargain Following Reaffirmed Outlook And Mixed Q3 Results?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/is-bruker-brkr-a-bargain-following-reaffirmed-outlook-and-mi
Bruker (BRKR) recently released mixed Q3 2026 results, including higher sales but also a larger goodwill impairment charge and a wider loss, while reaffirming its full-year outlook. Despite a recent share price decline, the stock has shown positive momentum over the past month and year-to-date. Analysts currently view Bruker as slightly undervalued, with a fair value of approximately $63.83.

Agilent's new 5987A GC/MS takes aim at costly sample reruns

https://www.marketscale.com/industries/sciences/agilents-new-5987a-gcms-takes-aim-at-costly-sample-reruns
Agilent has released its new 5987A GC/MSD system, designed to reduce costly sample reruns by offering faster scanning, a wider detector range, and GC Assist diagnostics. The system aims to mitigate rising carrier gas costs, particularly helium, and improve lab efficiency by consolidating multiple analytical runs into one. Key features include a wider dynamic range to reduce dilution reinjections and simultaneous dSIM/Scan for combined quantitation and library searching.

How Agilent's 5987A Rethinks the Single Quadrupole Mass Spectrometer

https://www.labmanager.com/how-agilent-s-5987a-rethinks-the-single-quadrupole-mass-spectrometer-36269
Agilent Technologies has launched the 5987A GC/MSD with GC Assist, a new single quadrupole mass spectrometer designed to reduce reruns, energy consumption, and unplanned downtime in routine GC/MS work. It features faster scanning, a wider dynamic range, and built-in diagnostics that monitor over 60 system parameters. This aims to help labs manage growing workloads, limited resources, and financial pressures from rising carrier gas costs.

Agilent launches genomic profiling solution for blood cancers By Investing.com

https://ca.investing.com/news/stock-market-news/agilent-launches-genomic-profiling-solution-for-blood-cancers-93CH-4946519
Agilent Technologies Inc. (NYSE:A) has launched SureSelect Cancer Research Pan Heme, a next-generation sequencing solution for genomic profiling of blood cancers. Developed in collaboration with Roswell Park Comprehensive Cancer Center, this solution integrates DNA and RNA profiling to detect various genomic alterations. It is designed for research use only and expands Agilent's portfolio for cancer research.
Advertisement

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

https://finance.yahoo.com/healthcare/articles/agilent-expands-tumor-profiling-portfolio-130000847.html
Agilent Technologies has launched SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) solution for comprehensive genomic profiling of hematologic malignancies. Developed with Roswell Park Comprehensive Cancer Center, this solution integrates DNA and RNA profiling, automated sample preparation, and bioinformatics into a streamlined workflow. It aims to provide researchers with deeper molecular insights into complex blood cancers, while simplifying laboratory demands and accelerating results.

Bruker Reaches a New 52-Week High at $66.54

https://247wallst.com/cards/bruker-brkr-enriched-price-move-01m71b9yrzjz7k8fmzfdz30p5z
Bruker (BRKR) stock closed at a new 52-week high of $66.54 on November 9, 2026, surpassing its previous peak by 2.76%. This surge is indicative of a broader positive trend within the scientific instrument and analytical toolmaker sector, as competitors like AMETEK, Thermo Fisher Scientific, and Agilent Technologies also saw gains. The significant rerating of Bruker's stock, which traded in the low $30s earlier in the year, suggests strong market confidence, with investors closely watching if the stock can maintain its new high.

Bio Rad Laboratories (BIO) Could Be 14% Overvalued After Elliott Interest And Earnings

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bio/bio-rad-laboratories/news/bio-rad-laboratories-bio-could-be-14-overvalued-after-elliot
Bio-Rad Laboratories (BIO) is considered 14% overvalued against its fair value of $335, despite strong third-quarter earnings and interest from Elliott Investment Management. The company's multi-year restructuring program aiming for significant cost savings and improved operating margins has encouraged investors, possibly inflating expectations. While a simple P/E ratio suggests a modest premium, the ongoing debate centers on whether the growth story or the multiple moving closer to peers poses a greater risk.

Agilent Technologies (A), What Is Drawing Fresh Attention To The Stock?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-technologies-a-what-is-drawing-fresh-attention-to-th
Agilent Technologies (A) is gaining attention following the launch of its 5987A mass selective detector with GC Assist and MassHunter 14 software, ahead of its Q4 earnings. The company has seen significant share price returns, including 19.72% over 90 days and 26.68% year-to-date, reflecting investor interest in its product innovation and strategic moves. While the stock is currently assessed as 4% undervalued based on a fair value of $181.05, its P/E ratio of 34.2x suggests a more demanding valuation compared to its fair ratio of 27.2x.

Proscia Joins Agilent in $240 Million Pathology Software Deal

https://www.mychesco.com/a/news/regional/proscia-joins-agilent-in-240-million-pathology-software-deal/
Agilent Technologies Inc. (NYSE: A) has completed a $240 million cash acquisition of Proscia, a digital pathology software provider, with potential additional payments up to $30 million based on performance. This acquisition expands Agilent's digital pathology business, integrating AI-enabled software into its clinical diagnostics and life sciences portfolio. Proscia's vendor-agnostic platform and FDA-cleared software enhance Agilent's capabilities in tissue-based diagnostics, pharmaceutical research, and drug development, positioning the company for growth in the estimated $5 billion pathology market.
Advertisement

Agilent Technologies Inc. stock underperforms Friday when compared to competitors despite daily gains

https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-underperforms-friday-when-compared-to-competitors-despite-daily-gains-8c6d3bf8-52eb5015ce76
Agilent Technologies Inc. (A) stock increased by 1.73% on Friday, closing at $174.76, despite underperforming compared to its competitors. The company's stock finished 4.50% below its 52-week high of $182.99. This occurred during a mixed trading session where the S&P 500 Index rose by 0.31%, while the Dow Jones Industrial Average fell by 0.46%.

Form 8K Agilent Technologies For: 6 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-6-november-93CH-4939794
This article announces that Agilent Technologies has filed a Form 8K on November 6th. The content of the filing itself is not detailed, but the article serves as an alert for investors interested in the company's latest corporate disclosures. It was published by Investing.com, a financial markets news source.

Form 8K Agilent Technologies For: 6 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-agilent-technologies--for-6-november-93CH-4965456
This article announces that Agilent Technologies has filed a Form 8K on November 6th. The Form 8K is a crucial SEC filing used by public companies to announce major events that shareholders should know about. The brief article, published by Investing.com, indicates the date of the filing but does not provide further details regarding its content.

Bruker (BRKR) Stock May Still Trade At A Discount As Q3 Results Land

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/bruker-brkr-stock-may-still-trade-at-a-discount-as-q3-result
Bruker's stock has seen a significant 46.0% gain over the past year. Despite this, a Discounted Cash Flow (DCF) analysis suggests the stock may still be undervalued, with an intrinsic value meaningfully above its current share price, supported by strong Q3 results and reaffirmed guidance. Both bullish and bearish "Narratives" for Bruker exist, focusing on different assumptions about future growth, profitability, and aftermarket contribution.

In Brief This Week: Personalis, IntelliGenome, Agilent, Bio-Techne, Labcorp, TwinStrand, More

https://www.genomeweb.com/news/gnw-personalis-intelligenome-agilent-bio-techne-twinstrand-20261106/
This article provides a brief overview of recent developments involving several companies in the genomics and diagnostics sector, including Personalis, IntelliGenome, Agilent, Bio-Techne, Labcorp, and TwinStrand. It highlights key updates from these companies, indicating ongoing activities and advancements in the industry.
Advertisement

How Investors May Respond To Agilent (A) New Mass Spectrometer Launch

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/how-investors-may-respond-to-agilent-a-new-mass-spectrometer
Agilent Technologies recently launched its 5987A single quadrupole mass selective detector with GC Assist and MassHunter 14, which integrates with their 8890B and 8860B gas chromatographs to improve lab efficiency, automation, and energy consumption. This launch aligns with Agilent's strategy to deliver high-end lab hardware, software, and services for steadier, higher-margin cash flows, especially by focusing on software and data-heavy workflows. While the new GC/MS system supports the investment narrative, risks include pressure on research budgets and integration complexity for advanced instruments and software.

Twist Bioscience Stock Sinks as Bear Cave Raises Valuation Concerns

https://www.benzinga.com/trading-ideas/movers/26/11/62935399/twist-bioscience-stock-sinks-as-bear-cave-raises-valuation-concerns
Twist Bioscience (NASDAQ: TWST) shares plunged following a report from The Bear Cave, owned by Hunterbrook Media, which suggested the company's stock valuation is inflated compared to its fundamentals and rivals. The report highlighted that despite being an "ordinary lab supplier," Twist trades at a premium, faces significant competition, and questioned if a past 95% stock value drop could recur. The stock was down over 10% following the report.

Here’s How Much You Would Have Made Owning Agilent Technologies Stock In The Last 10 Years

https://www.benzinga.com/news/26/11/62931251/here-s-how-much-you-would-have-made-owning-agilent-technologies-stock-last-10-years
Agilent Technologies (NYSE: A) has outperformed the market over the last decade, generating an average annual return of 14.24%. An initial investment of $100 in Agilent stock ten years ago would now be worth $381.67, highlighting the significant impact of compounded returns on cash growth over time.

Agilent Closes $240M Acquisition of Digital Pathology Software Maker Proscia

https://clpmag.com/lab-management/company-news/agilent-acquires-proscia-digital-pathology-software/
Agilent Technologies has completed its acquisition of Proscia, a digital pathology software provider, for $240 million in cash with potential additional payments. The acquisition adds Proscia's FDA-cleared, vendor-agnostic software platform to Agilent's portfolio, enhancing its capabilities in clinical diagnostics, biopharma, and life sciences research. This move is expected to advance AI-enabled pathology workflows, accelerate drug discovery, and expand companion diagnostics solutions.

Agilent Technologies' Q4 Earnings on Deck: What's in Store for the Stock?

https://www.tradingview.com/news/zacks:f95ef7527094b:0-agilent-technologies-q4-earnings-on-deck-what-s-in-store-for-the-stock/
Agilent Technologies is set to announce its fourth-quarter fiscal 2026 results on November 23, with analysts expecting revenues of $1.99 billion and EPS of $1.72. The company's prior quarter saw an EPS of $1.62, beating estimates. Key segments like Life Sciences and Diagnostics Markets Group (LDG) and Applied Markets Group (AMG) are expected to drive growth, especially in areas like Liquid Chromatography and semiconductor production tools.
Advertisement

Agilent (A) Stock Looks Overvalued Following Its 66% Three Year Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/agilent-a-stock-looks-overvalued-following-its-66-three-year
Agilent Technologies (A) has experienced a significant 65.6% stock increase over the past three years, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests that the stock, trading at $177.17, may be overvalued as its intrinsic value based on future cash flows is estimated to be substantially lower. While recent acquisitions like Proscia, which add recurring revenue software, could influence investor confidence, the model still indicates the stock is above its fair value.

Software for examining tissue, trusted by 16 of the top 20 drug companies, now belongs to Agilent.

https://www.stocktitan.net/news/A/agilent-completes-acquisition-of-b9dljco8wtkq.html
Agilent Technologies Inc. has completed its acquisition of Proscia, a leading provider of digital-pathology software, for $240 million in cash with potential additional payments. This acquisition strengthens Agilent's pathology portfolio, adds recurring software revenue, and establishes a platform for scientific intelligence in tissue-based precision medicine. Proscia's FDA 510(k) cleared platform, trusted by major pharmaceutical companies, enhances Agilent's capabilities across clinical diagnostics, biopharma, and life-sciences research.

Harvard Bioscience stock faces Q3 test as margin concerns persist

https://www.ad-hoc-news.de/boerse/news/nebenwerte/harvard-bioscience-stock-faces-q3-test-as-margin-concerns-persist/70460235
Harvard Bioscience (HBIO) is heading into its Q3 report with increased revenue expectations, but investors are closely watching its gross margins and cash generation. While the company raised its full-year growth outlook, the adjusted EBITDA margin target remains stable, putting pressure on management to demonstrate that revenue growth can coexist with stable profitability. The upcoming earnings call on November 10, 2026, will be critical for investors to assess the company's performance in balancing growth and margin stability.

Where Does Agilent Technologies (A) Value Sit After Proscia?

https://sg.finance.yahoo.com/news/where-does-agilent-technologies-value-232350873.html
Agilent Technologies (A) has seen significant stock gains over the past three years, prompting questions about whether its current US$177.17 share price is justified by its expected cash generation, especially after the acquisition of Proscia and new AI-enabled lab instruments. While discounted cash flow models suggest the stock might be overvalued, the market seems to be factoring in the recurring revenue from software and services, which analysts believe could support its current valuation. Investors are encouraged to consider the company's growth paths, profitability, and management incentives alongside valuation models.

Revenue rose to $145.5M at Cytek Biosciences (CTKB), but its nine-month loss widened.

https://www.stocktitan.net/sec-filings/CTKB/10-q-cytek-biosciences-inc-quarterly-earnings-report-3d3fbb0140d1.html
Cytek Biosciences (CTKB) reported increased revenue for both the third quarter and the first nine months of 2026, reaching $53.2 million and $145.5 million, respectively. However, the company's net loss widened to $37.1 million for the nine-month period, up from $22.5 million in the prior year, primarily due to higher litigation expenses and bad debt reserves. The company is also involved in ongoing patent litigation with Beckman Coulter, Inc., where a jury awarded $56.11 million in past damages against Cytek, though the judgment is not final.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement